Since Akt is critical for the survival of tumor cells, we decided to explore if chronic exposure of cells to rapamycin, the pharmacologic method of mTORC2 inhibition, could synergize with 17-AAG to suppress myeloma cell lines proliferation in vitro. This evidence concerns the gene AKT1 and plasma cell myeloma.